spacer
home > pmps > autumn 2008 > mes gets you to market quicker
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

MES Gets You to Market Quicker

Probably the biggest single driver for any manufacturer in the pharmaceutical industry has to be the time it takes to get a potential product through the research and development phases and out to market.

With R&D costs to bring a new drug to release approximated at $1 million a day, only when a product is in daily use does the huge investment undertaken by drug companies seeking the next blockbuster product begin to pay back.

There are plenty of examples, across many industries, of companies being late to market with a product, only to find further down the line that competitors’ products have subsequently appeared, with a resulting substantial hit in potential operating profits. Once a company is in the process of research...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Mark Perry has held a number of senior positions, including Sales Director for ABB Process Instrumentation & Micro Control Systems and General Manager for Rockwell Automation EMEA Asset Management. He joined Siemens in 2003 as General Sales Manager for the Process Instrumentation Group before moving into the automation and drives process sector, heading up teams focusing on the chemical/pharmaceutical, food and beverage and oil and gas sectors. In 2007, Mark took up the position as Business Manager for the Siemens UK MES group, with responsibility for, among others, the pharmaceutical industry.
spacer
Mark Perry
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration

Philadelphia, PA – November 14, 2019: Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement